Skip to content
lifestyle.gopreneurs.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
IDEAYA Biosciences, Inc.
IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers
June 15, 2026
IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
June 10, 2026
IDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded Warrants
June 8, 2026
IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
June 8, 2026
IDEAYA Biosciences Announces Clinical Collaboration with Roche in MTAP-Deleted RAS-Mutant Pancreatic Cancer
June 3, 2026
IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late-Breaking Oral Presentation at ASCO
June 1, 2026
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
May 29, 2026
IDEAYA Biosciences Announces Participation at the 2026 Jefferies Global Healthcare Conference
May 26, 2026
IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update
May 22, 2026
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
May 22, 2026
1
2
3
Next Page
→